Details

Extracellular Targeting of Cell Signaling in Cancer


Extracellular Targeting of Cell Signaling in Cancer

Strategies Directed at MET and RON Receptor Tyrosine Kinase Pathways
1. Aufl.

von: James W. Janetka, Roseann M. Benson

142,99 €

Verlag: Wiley
Format: PDF
Veröffentl.: 10.05.2018
ISBN/EAN: 9781119300205
Sprache: englisch
Anzahl Seiten: 488

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy.  With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development. A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment. 
Ch 1 -   Discovery and function of the HGF/MET and the MSP/RON kinase signaling pathways in cancerSilvia Benvenuti, Melissa Milan, and Paolo M. Comoglio; Candiolo Cancer Institute, Italy Ch 2 -   The role of HGF/MET and MSP/RON signaling in tumor progression and resistance to anticancer therapyLidija Klampfer; ProteXase Therapeutics, Inc., USA Benjamin Yaw Owusu; University of Alabama at Birmingham School of Medicine, USA Ch 3 - HGF Activator (HGFA) and its inhibitors HAI-1 and HAI-2: Key players in tissue repair and cancerHiroaki Kataoka and Takeshi Shimomura; University of Miyazaki, Japan Ch 4 - Physiological Functions and Role of Matriptase in CancerFausto A. Varela, Thomas E. Hyland, and Karin List; Wayne State University, USA Ch 5 - The cell-surface, transmembrane serine protease Hepsin: discovery, function and role in cancerDenis Belitškin*, Shishir Mani Pant*, Topi Tervonen, and Juha Klefström; University of Helsinki, Finland Ch 6 - Targeting HGF with antibodies as an anticancer therapeutic strategyDinuka M. De Silva, Arpita Roy, and Donald P. Bottaro; National Cancer Institute, USA Ch 7 - MET and RON Receptor Tyrosine Kinases as Therapeutic Antibody Targets for CancerMark Wortinger, Jonathan Tetreault, Nick Loizos, and Ling Liu; Eli Lilly, USA Ch 8 - Inhibitory antibodies of the proteases HGFA, matriptase, and hepsinDaniel Kirchhofer, Charles Eigenbrot, and Robert A. Lazarus; Genentech, USA Ch 9 - Inhibitors of the growth-factor activating proteases matriptase, hepsin and HGFA:  Strategies for rational drug design and optimizationJames W. Janetka; Washington University, USA Robert A. Galemmo, Jr.; ProteXase Therapeutics, Inc., USA Ch 10 - Cyclic peptide serine protease inhibitors based on the natural product SFTI-1Jonathan M. Harris; Queensland University of Technology, Australia Blake T. Riley, Olga Ilyichova, David E. Hoke, and Ashley M. Buckle; Monash University, Australia Ch 11 - Screening combinatorial peptide libraries in protease inhibitor drug discoveryMarcin Poreba and Paulina Kasperkiewicz; Sanford Burnham Prebys Medical Discovery Institute, USA Wioletta Rut and Marcin Drag; Wroclaw University of Technology, Poland Ch 12 -  Chemical probes targeting proteases for imaging and diagnostics in cancerPedro Gonçalves and Steven H. L. Verhelst; University of Leuven, Belgium Ch 13 - Cancer Diagnostics of protease activity and metastasisTimothy J. O’Brien and John Beard; Stage I Diagnostics, Inc., USA Ch 14 - Roles of pericellular proteases in tumor angiogenesis: therapeutic implicationsJanice M. Kraniak, Raymond R. Mattingly, and Bonnie F. Sloane; Wayne State University School, USA
Dr. James W. Janetka is an Associate Professor at Washington University School of Medicine, and has over 20 years of medicinal chemistry and drug discovery experience within both industry and academia.  He has published 50 peer-reviewed manuscripts and holds 20 US patents in oncology and infectious disease. Roseann Benson is a chemical engineer turned scientific writer and editor.  As a consultant for Harvard and Washington University Medical Schools, she has edited and contributed to manuscripts and books that have been published by Wiley, CUP, Nature, and Science.
International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy.  With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development. A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment. 

Diese Produkte könnten Sie auch interessieren:

Cancer Prevention and Screening
Cancer Prevention and Screening
von: Rosalind A. Eeles, Christine D. Berg, Jeffrey S. Tobias
EPUB ebook
108,99 €
Cancer Prevention and Screening
Cancer Prevention and Screening
von: Rosalind A. Eeles, Christine D. Berg, Jeffrey S. Tobias
PDF ebook
108,99 €
The Consumer-Resource Relationship
The Consumer-Resource Relationship
von: Claude Lobry
EPUB ebook
125,99 €